Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5971-5980 Newer>

The Motley Fool October 27, 2009 Brian Orelli	Back From the Dead: A Public Option The government-run public option, which seemed all but dead just a few weeks ago, much to the joy of health insurers, is looking like it might make a comeback.
The Motley Fool October 26, 2009 Brian Orelli	For Tysabri, 23 Is 10 Too Many The side effect rate is important.
The Motley Fool October 26, 2009 Dave Mock	A Big Upgrade for Electro-Optical Sciences This bullish call comes from more than just one analyst. The Food and Drug Administration has put Electro-Optical Sciences' melanoma detection device on the fast track.
Chemistry World October 23, 2009 Matt Wilkinson	What's in a pill? Buying cheap drugs over the internet is well known to be a risky business. But the sinister menace of the 'falsified' active pharmaceutical ingredient gets far less publicity.
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool October 23, 2009 Brian Orelli	Merck-Schering Doesn't Look So Good Revenue is stagnant; let's hope that pipeline pans out.
The Motley Fool October 23, 2009 Brian Orelli	Not 50% Growth, but We'll Take It Double-digit growth is still pretty good for Celgene.
The Motley Fool October 22, 2009 Brian Orelli	Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated.
<Older 5971-5980 Newer> Return to current articles.